Medicare maintains limits on Eisai’s new Alzheimer’s drug

The Centers for Medicare and Medicaid Services will retain its tight restrictions on paying for new Alzheimer’s drugs, stating that it hasn’t yet seen enough data to demonstrate Eisai and Biogen’s Leqembi meets its standards for coverage. Following an accelerated approval of Biogen’s Aduhelm last year, the agency said it would cover only patients who are enrolled in clinical trials.